isabelobrien, Author at European Medical Journal - Page 57 of 68

Talking to Rob Jekielek

Rob Jekielek, Managing Director, The Harris Poll, discusses the evolving public perceptions of the pharma industry.

Talking to José Maria Guido Avila

José Maria Guido Avila, Global Lead HCP Marketing, Sanofi, shares his thoughts on appropriate metrics measure the success of virtual events.

Talking to Ipsen's UK & Ireland team

Four Ipsen colleagues discuss the fabric and value of high-performing teams, especially against the backdrop of COVID-19.

Was the pandemic the rebrand pharma needed?

The pharmaceutical industry has long struggled with its reputation, but 2020 offered an opportunity for reform. How has their response to the crisis affected perceptions, or is misinformation still getting in the way?

Securing patient care beyond COVID-19

While attention was channelled into COVID-19, patients awaiting other treatments were deprioritised. How can pharma ensure no patients are left behind?

Roundtable: a conversation about drug pricing

Hear from two thought leaders who share their passion for health economics, their thoughts on non-traditional models, and how they predict drugs will be costed in the future.

Can medical affairs help reduce health inequalities?

COVID-19 has revealed a pandemic of another kind: existing health inequities between population groups. We explore the role and responsibility of medical affairs teams in addressing imbalances and forging a fairer and more inclusive health landscape for the future

Finding a fast lane for precision medicine

What are the obstacles in the way of rolling out precision medicine and how can medical affairs professionals overcome them to fast-track adoption for patients?

Let's talk about sexual health

What role can medical affairs professionals play in filling this knowledge gap as they communicate the importance of sexual health?

Is pharma ready to stop cyber attacks in their tracks?

Cyber-attacks have become a mounting threat to the pharmaceutical industry over the past year, putting COVID-19 research data as well as supply and distribution chains at risk. We explore what can pharma learn from more experienced industries as they try to mitigate hacking